AbbVie Inc

AbbVie Inc. discovers develops manufactures and sells pharmaceuticals worldwide. The company offers Humira a therapy administered as an injection for autoimmune intestinal Behçet's diseases and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis psoriatic disease and Crohn's disease; Rinvoq a JAK inhibitor to treat rheumatoid and psoriatic arthritis ankylosing spondylitis atopic dermatitis axial spondyloarthropathy and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies. It also provides facial injectables plastics and regenerative medicine body contouring and skincare products; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; and Ubrelvy for the acute treatment of migraine with or without aura in adults; Qulipta for episodic migraine. In addition the company offers Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure(IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Restasis a calcineurin inhibitor immunosuppressant indicated to increase tear production; and eye care products. Further it provides Mavyret/Maviret to treat chronic hepatitis C virus (HCV) genotype 1-6 infection and HCV genotype 1 infection; Creon a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer endometriosis and central precocious puberty and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; I-Mab Biopharma; Genmab A/S; Janssen Biotech Inc.; and Genentech Inc. The company was incorporated in 2012 and is headquartered in North Chicago Illinois.